Technology evaluation: huN901-DM1, ImmunoGen

Curr Opin Mol Ther. 2005 Aug;7(4):394-401.

Abstract

ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer.

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacokinetics
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • CD56 Antigen
  • Carcinoma, Small Cell / drug therapy*
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Humans
  • Lung Neoplasms / drug therapy*
  • Maytansine / analogs & derivatives
  • Prodrugs / therapeutic use*
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CD56 Antigen
  • Prodrugs
  • Maytansine
  • Trastuzumab
  • Ado-Trastuzumab Emtansine